Jus-Inventors Logo

Jus-InventorsTM

A complete advisory solution for protecting the intellectual assets of inventors
Jus-Inventors is a complete advisory solution for protecting the intellectual assets of inventors across all industries. Whether an individual with a new idea or a small company engineering scientific, medical, technological or other innovations, Jus-Inventors helps you negotiate fair investment agreements to protect your intellectual capital.
Jus-Inventors can direct individual inventors and small companies to investment resources designed to empower your innovation, retain your rights to your invention and empower you to profit from and control your invention in the marketplace.
Jus-Inventors helps inventors of all types ensure the majority value of their creations remains within their intellectual and financial control.
Jus-Inventors protects inventors against exploitive and predatory investment structures that enable third-party investors to control and derive the majority financial, intellectual and brand benefit from the creative assets of the inventor.
AtJus-Inventors, we ensure all elements of an invention’s future earnings in the marketplace remained controlled by the inventor -- and not a third-party investment company.
Why Jus-Inventors?

Too often inventors in need of start-up and long-term capital have been exploited by investment companies that fund the development of an innovation and skew their contracts to gain permanent control over the invention. Jus-Investors prevents the hard work and passions of the most gifted and ambitious inventors and small companies from being manipulated by larger funding organizations.

Inventors whose creations change lives, cure illness and effect positive change in the world are protected through Jus-Inventors from ever succumbing to the vulnerable position of being fully stripped of their invention, deriving no patent or significant profit from their own creation.

How Jus-Inventors Works

Jus-Investors delivers an advisory team of highly credentialed legal, investment, regulatory, corporate, scientific and marketing experts to protect and enhance the capability of inventors to fund development of and market viable innovations. Jus-Investors helps inventors obtain appropriate start-up capital without surrendering majority ownership of their innovations. We empower inventors to retain control and receive credit for and profit from inventions that effect positive change in the world.

With Jus-Inventors,

  • Securely upload a start-up capital and funding document for review by our team
  • Receive legal counsel from highly qualified attorneys
  • Eschew red flags often inherent in funding and investment contracts
  • Have initial agreements re-drafted to protect your intellectual capital and the profit you derive from your own invention
  • You Can...

  • Receive assistance in negotiating fair agreements that empower you to innovate and invent without sacrificing control over the marketability and eventual profit of your creation
  • Obtain funding from ethical capital sources that partner with inventors to support their innovations and enter a receptive marketplace
  • Position your invention to transform into a profit stream that permanently benefits your own enterprise
  • Don’t Go It Alone

    At Jus-Inventors, we realize that start-up capital and long-term investment funding may be the only limit on your ability to innovate and introduce your creations to the marketplace. Don’t go it alone in negotiating with investment companies – Jus-Inventors is here for you. We offer the guidance and capital resources you need, when you need it, on demand.

    Simply register via laptop, desktop, smartphone or android device and fill out the form.
    We'll do the rest for you!


    Learn More
    Jus-Law Smart Phone UI
    Fully Secure and Confidential

    Jus-Inventors offers a hyper-secure, Apple-approved and Android-compatible platform with integrated blockchain timestamp technology. Any documents you exchange with us remain fully confidential, just as our voice and video conferencing are.

    At Jus-Inventors, we are your ally in helping you introduce your invention to the world, without sacrificing your innate rights to your own intellectual capital. We empower you to brand your invention as your own. Take pride in changing lives and changing the world through your ingenuity. With Jus-Inventors, you can obtain capital to innovate and remain in control of your invention.

    JOIN

    Join the Jus-Inventors team of accomplished attorneys and begin bidding on the legal assignments of your choosing.

    Sign Up

    Ask Us How

    Ask the Jus-Inventors team of international experts how Jus-Inventors can work for you. Get your questions answered!

    Connect

    Our Team

    Our Jus-Inventors team is fueled by a passion to promote innovation and undercover the transformational inventions of tomorrow today. We are a dedicated group of attorneys, corporate advisors, regulatory experts, scientists and marketers who work together to support individual inventors and small companies whose ingenuity and entrepreneurial capabilities effect positive change, transform lives and create a better global future.

    Image

    Beatrice O'Brien

    FOUNDER/CHAIR/CEO

    Beatrice O’Brien brings immeasurable value to JusLaw, not just her passion for the Law and the Legal Industry but also her over 20 years of legal experience with Wall Street Firms, such as, Cadwalder Wickersham & Taft and with international firms in Australia and the UK.

    She has worked with high profile clients, such as, Warren Buffet and on high-profile cases, such as, the largest reorganization and restructuring cases in US, UK, and Australian corporate history.

    Beatrice is a graduate of Bond University the only Private Law School in Australia with a Law Degree and is a graduate of Harvard Law School Executive Program. She speaks fluent Hindi. Beatrice leveraged her extensive experience to create the first of its kind marketplace revolutionizing the legal industry.

    Image

    John C. Ferrara

    ADVISORY BOARD

    John C. Ferrara is on the Advisory Board of JusLaw with extensive experience in corporate governance, business strategy, finance, operations, business development, capital raising, risk management, cash management, M&A and company exits.

    John has served on the Boards of four (4) public companies; including GAMCO Investors, Inc. (NYSE:GBL) and has been the CFO of several public companies; including The Street Inc. (NASDAQ:TST), EDGAR Online, Inc.(NASDAQ:EFGR) and Renaissance Communications Corp. (NYSE:RRR).

    John has over twenty years of C-level experience at public, private and PE portfolio entrepreneurial companies; including start-ups, turnarounds, and high growth organizations, with a prior background at two Fortune 500 corporations (NBC & American Express) and a Big 4 public accounting firm (Deloitte).

    Image

    Oliver Ramsbottom

    ADVISORY BOARD MEMBER

    Partner with McKinsey & Company for over 20 years, based out of Hong Kong & Tokyo. Oliver brings to JusLaw over 20 years international experience in strategy and business development and start-ups. He is a graduate of Oxford & Harvard Business School.

    Mr. Ramsbottom speaks fluent Mandarin.

    Image

    Jack Habert

    ADVISORY BOARD MEMBER

    Senior Vice President at Investment Bank Jeffries Group LLC based in New York. Jack brings to JusLaw expertise in the legal requirements for online platform businesses having been advisor to government entities including the Securities and Exchange Commission (SEC) and the Commodities Futures Trading Commission (CFTC) on the development of new legal regulation.

    Jack experience expands also to his practice of law for AM LAW 100 Firm, Willkie Farr Gallagher bringing high caliber legal network to JusLaw platforms.

    Image

    Jason Stiehl

    ADVISORY BOARD MEMBER

    Partner Loeb & Loeb LLP based in New York. Jason brings to JusGlobal a large legal network across consumer class defenses as well as corporate espionage litigation and consulting. He was named a “Best Lawyer” in 2021 Trade Secrets Law: The Best Lawyers in America.

    Dona Zimmerman

    Dona Zimmerman

    ADVISORY BOARD MEMBER

    Dona has over 30 years in the legal education industry. She was co-founder and vice president of PMBR, a national preparation course for the Multistate Bar Examination which she sold to Kaplan in 2006 for over 200m. Dona is currently the Founder and President of Your Bar Exam Tutor.com. Being a renowned authority on legal education, Dona brings to JusLaw a broad view of the legal industry and legal education to JusLaw.

    Duane Lakings
    Duane Lakings
    CHIEF SCIENTIFIC OFFICER

    Duane Lakings delivers a broad array of expertise in various primary areas of drug discovery and development to the JusGlobal enterprise. Dr. Lakings is experienced across nonclinical pharmacology, pharmacokinetics and toxicology as well as clinical safety, efficacy, chemistry, manufacturing and control of drug substances and proposed drug products and regulatory affairs. He assists pharmaceutical and biotechnology companies in evaluating results from their drug discovery and development programs, including document preparation, protocol design and implementation across multiple disciplines, as well as further evaluation of drug candidates to support regulatory submission.

    Dr. Lakings has served as president of Texas-based Drug Safety Evaluation and was director of drug safety evaluations at Regeneron Pharmaceuticals in Tarrytown, New York as well as a senior research investigator II at BMS-PRI (Princeton, NJ). He has been a research scientist at The Upjohn Company in Michigan and he has conducted research for the National Cancer Institute and the University of Missouri-Columbia.

    Dr. Lakings has extensive publishing credits. He has authored or co-authored 44 refereed papers and 150 company-specific papers, nine book chapters on drug development, 26 abstracts for oral/poster presentation, eight commissioned drug candidate evaluation reviews and a 300-page report on biological contract research organizations (CROs).

    Image
    Eyal Ron
    SENIOR MANAGING DIRECTOR, PRODUCT DEVELOPMENT

    Dr. Eyal Ron adds value for Jus Pharma clients in the pharmaceutical, biotechnology and medical device space by accelerating the timeline toward the value inflection point. Dr. Ron delivers an entrepreneurial thought process coupled with science-based evaluation to enhance the overarching enterprise value regarding product candidates, without creating a need for costly infrastructure to foster growth.

    With three decades of experience in the development of drugs, biomaterials, devices and drug delivery systems, Dr. Ron has become known for combining science with sound business strategy, making him an ideally qualified expert on the JusGlobal team. He developed and implemented the scientific, regulatory and clinical strategy for several companies. Dr. Ron offers extensive depth in the total therapeutic development process including project management, clinical trials, regulatory compliance and approval, drug delivery systems, quality control and scale-up. Dr. Ron has authored more than 100 papers, book chapters and abstracts. He is also the inventor of 50 patents, principally in drug formulations, drug delivery, tissue engineering and biomaterials.

    He has been a founder or principal formulator of biotech companies, bringing seven new medications to market. He has held the position of COO, CTO and CSO, director of pharmaceutical development and principal investigator at several pharmaceutical and biotech firms.

    Dr. Ron received a PhD from Brandeis University and has completed post graduate study at Massachusetts Institute of Technology. He earned a BS at Tel Aviv University.

    Image

    Dr. Evan Siegel, Ph.D.

    CHIEF REGULATORY OFFICER

    Dr. Evan Siegel adds value for Jus- Pharma clients in the pharmaceutical, biotechnology and medical device space in the Regulatory Affairs and Product Development.

     

    Dr. Siegel served as Chief Executive Officer of OXO Chemie Inc. from 1997 to 1999. Before he joined OXO Chemie, he was the Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. Prior to that he was Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., in Research Triangle Park, North Carolina. He has served in regulatory affairs and executive positions in the pharmaceutical (Astra, Syntex, and OXO Chemie), Genetics Testing Industries (Medical Science Systems); and trade association environments.

     

    Dr. Siegel has also held positions as a Toxicology Reviewer at the US Food and Drug Administration and California Department of Health Services and, at the latter, was Chief of Special Services.

     

    He attended Bucknall University where he received a Bachelor’s of Science degree in Physics; Rutgers University, where he earned a Masters of Science degree in Radiological Health/Health Physics; the Waksman Institute of Microbiology where he earned both his Masters and Doctor of Philosophy degrees in Virology and Molecular Biology, and was awarded Postdoctoral Fellowships in Medical Genetics and Genetics Counselling at the University of North Carolina at Chapel Hill.

     

    Dr. Siegel is an Adjunct Professor at the University of Queensland and the Centre for the Study of Preclinical Drug Development, Brisbane, Australia, and a member of the California Lieutenant Governor’s Biotechnology Advisory Group to the California Council for Economic Development. 

    Image
    Patricia Blaine
    SENIOR MEDICAL WRITER

    Patricia Blaine is a registered respiratory therapist, university instructor and accomplished medical writer. She has served as a consultant in clinical trial protocols for leading pharmaceutical companies such as Eisai, Daiichi Sankyo, Forest Laboratories and Schering-Plough.

    Ms. Blaine has been a senior director of medical writing and a staff medical writer for Oxford Research, Corning-Besselaar and Schering-Plough. She has been director of clinical education at the University of Medicine and Dentistry of New Jersey (UMDNJ). Ms. Blaine provided medical writing for a poster presented at a psychiatric conference focusing on a Phase IV multi-site investigatory study on carmbamazepine.

    Patricia Blaine earned a Master’s degree in Education with a concentration in Allied Health Education from Rutgers University and a Bachelor of Arts in Psychology and English from Seton Hill University (Pennsylvania).

    jus-law logo

    Jus-InventorsTM